Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any systemic lupus erythematosus in which the cause of the disease is a variation in the C1QA gene.
Biomarker and diagnostic research for systemic lupus erythematosus related to C1QA has been reported in the published literature.
No clinical trials have been registered for systemic lupus erythematosus related to C1QA.
3 publications have been identified in PubMed for systemic lupus erythematosus related to C1QA. Research spans Diagnostic / Biomarker (33%), Review / Meta-Analysis (33%), and Case Report / Case Series (33%).
Zhang L (2026). [PMID: 42056344](https://pubmed.ncbi.nlm.nih.gov/42056344/). *Clin Rheumatol*. [Diagnostic / Biomarker]
Parlar K (2025). [PMID: 40316395](https://pubmed.ncbi.nlm.nih.gov/40316395/). *Reumatologia clinica*. [Case Report / Case Series]
Vélez N (2024). [PMID: 39836840](https://pubmed.ncbi.nlm.nih.gov/39836840/). *Biomedica : revista del Instituto Nacional de Salud*. [Review / Meta-Analysis]
Data assembled from 2 of 12 sources · Last updated Nov 4, 2026, 6:15 AM UTC
AI-curated news mentioning systemic lupus erythematosus related to C1QA
Updated Oct 19, 2026
A study reports sustained improvement in patients with systemic lupus erythematosus-associated pulmonary arterial hypertension following CD19 CAR T-cell therapy over one year. This research highlights the potential of CAR T-cell therapy in treating complex rare diseases.
A case study highlights the occurrence of Staphylococcus aureus purulent myopericarditis and cardiac tamponade in a patient with systemic lupus erythematosus. This research contributes to understanding the complications associated with systemic lupus erythematosus.
Recent research highlights immunosuppressant-refractory multifaceted immune dysregulations in systemic lupus erythematosus. This study provides insights into the complex immune mechanisms underlying the disease, which may inform future therapeutic strategies.
Roche announces the MHRA approval of Gazyvaro for systemic lupus erythematosus, providing a new treatment option for patients. This approval enhances the therapeutic landscape for a disease that affects millions worldwide.